Vandana (Gupta) Abramson, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

VandanaGupta(Gupta)AbramsonMD

Oncology Nashville, TN

Breast Cancer, Hematologic Oncology

Associate Professor, Medicine, Vanderbilt University School of Medicine

Dr. Abramson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Abramson's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 2003 - 2006
  • Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
  • University of Chicago Pritzker School of MedicineClass of 2000

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2020 - 2021
  • AL State Medical License
    AL State Medical License 2020 - 2020
  • TN State Medical License
    TN State Medical License 2010 - 2021
  • TN State Medical License
    TN State Medical License 2008 - 2021
  • PA State Medical License
    PA State Medical License 2003 - 2008
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • A Brighter Outlook for Metastatic Breast Cancer
    A Brighter Outlook for Metastatic Breast CancerNovember 1st, 2019
  • Vanderbilt Ingram Cancer Center’s Super Star Makes Every Month Breast Cancer Month
    Vanderbilt Ingram Cancer Center’s Super Star Makes Every Month Breast Cancer MonthOctober 19th, 2019
  • Grant Strengthens Breast Cancer Research Efforts
    Grant Strengthens Breast Cancer Research EffortsAugust 22nd, 2019
  • Join now to see all

Grant Support

  • Pet-Mri For Assessing Treatment Response In Breast Cancer Clinical TrialsNational Cancer Institute2010–2012
  • AKT Inhibitor Mk-2206 For Breast Cancers With A PIK3CA Mutation AND/OR PTEN LossNational Cancer Institute2011

Professional Memberships

Hospital Affiliations